Regulus Therapeutics Inc.
RGLS
Rang in aandelen
#17335
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Aandeelprijs
$8.16
Laatst gesynchroniseerd: 2025-06-26
Marktkapitalisatie
$234.57M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-56.96%
Land
US
Handel Regulus Therapeutics Inc. (RGLS)
Categorie
Healthcare
Winst voor Regulus Therapeutics Inc. (RGLS)
Winst in Mar 2024 TTM: $-466.89M
Volgens de meest recente financiële verslagen van Regulus Therapeutics Inc. bedraagt de huidige winst van het bedrijf $-466.89M. In 2022 behaalde het bedrijf een winst van $18.79M, een stijging ten opzichte van de winst van 2021, die $-672.17M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Regulus Therapeutics Inc. van 2002 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-466.89M | 121.21% |
| 2023 | $-211.06M | -1,222.99% |
| 2022 | $18.79M | -102.80% |
| 2021 | $-672.17M | -2,553.84% |
| 2020 | $27.39M | -122.92% |
| 2019 | $-119.51M | 71.97% |
| 2018 | $-69.50M | -15.80% |
| 2017 | $-82.54M | 31.05% |
| 2016 | $-62.99M | -381.25% |
| 2015 | $22.40M | -529.58% |
| 2014 | $-5.21M | -135.49% |
| 2013 | $14.69M | 264.74% |
| 2012 | $4.03M | -72.78% |
| 2011 | $14.80M | -15.98% |
| 2010 | $17.61M | -5.77% |
| 2009 | $18.69M | -25.44% |
| 2008 | $25.07M | 0.00% |
| 2007 | 0.00 | -100.00% |
| 2006 | $6.96M | 15.15% |
| 2005 | $6.04M | 1,478.98% |
| 2004 | $382.53K | -107.32% |
| 2003 | $-5.22M | -79.57% |
| 2002 | $-25.56M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -1,229.80% |
US
|
|
| $-3.09B | 561.18% |
US
|
|
| $-4.02B | 760.20% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -517.80% |
NL
|
